Disease · MONDO_0005068

myocardial infarction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. myocardial infarction. Diseases, record MONDO_0005068. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005068

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: myocardial infarction; Open Targets
Open Targets ID: MONDO_0005068; Open Targets
Other names: Attack - heart, Cardiac infarction, Cardiac infarction, NOS, Heart attack, NOS, Infarct, Myocardial, Infarction of heart, Infarction of heart, NOS, Infarction, Myocardial, Infarctions, Myocardial, Infarcts, Myocardial, MI, MI - Myocardial infarction, Myocardial Infarctions, Myocardial Infarcts, Myocardial infarction (disorder), Myocardial infarction NOS, heart attack, infarction (MI), myocardial, myocardial infarct, myocardial infarction (disease), myocardial infarction, (MI); Open Targets
Disease Ontology: DOID:5844; Disease Ontology
MeSH: D009203; MeSH
NCI Thesaurus: C27996; NCI Thesaurus
Highest stage of its drugs: Approval, for 55 of its 248 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs248

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TICAGRELOR	CHEMBL398435	Small molecule	Approval	DailyMed and PMDA	61	58	58	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Approval	EMA Human Drugs	90	56	55	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	40	30	30	Drugs and targets
PRASUGREL	CHEMBL1201772	Small molecule	Approval	EMA Human Drugs	29	27	26	Drugs and targets
COLCHICINE	CHEMBL107	Small molecule	Approval	ClinicalTrials.gov, at phase 4	14	13	13	Drugs and targets
TENECTEPLASE	CHEMBL2108791	Enzyme	Approval	EMA Human Drugs and TTD	10	7	6	Drugs and targets
EPTIFIBATIDE	CHEMBL1174	Protein	Approval	EMA Human Drugs	9	7	7	Drugs and targets
ALTEPLASE	CHEMBL1201593	Enzyme	Approval	DailyMed	7	6	5	Drugs and targets
CANGRELOR	CHEMBL334966	Small molecule	Approval	FDA	7	6	6	Drugs and targets
VALSARTAN	CHEMBL1069	Small molecule	Approval	DailyMed	75	5	5	Drugs and targets

1 to 10 of 248

See all 248 drugs

Targets221

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Adrenergic receptor beta	11	Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
P2RY12	P2Y purinoceptor 12	9	Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor; Purinergic receptor P2Y12 negative allosteric modulator	Approval	https://conductscience.org/library/genes/64805	Drugs and targets
ACE	Angiotensin-converting enzyme	8	Angiotensin-converting enzyme inhibitor	Approval	https://conductscience.org/library/genes/1636	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	7	HMG-CoA reductase inhibitor	Approval	https://conductscience.org/library/genes/3156	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	6	Type-1 angiotensin II receptor antagonist	Approval	https://conductscience.org/library/genes/185	Drugs and targets
SERPINC1	Antithrombin-III	6	Antithrombin-III activator	Approval	https://conductscience.org/library/genes/462	Drugs and targets
ADRB2	Adrenergic receptor beta	5	Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
DPP4	Dipeptidyl peptidase 4	5	Dipeptidyl peptidase IV inhibitor	Approval	https://conductscience.org/library/genes/1803	Drugs and targets
INSR	Insulin receptor	5	Insulin receptor agonist	Phase 3	https://conductscience.org/library/genes/3643	Drugs and targets
ITGA2B	Integrin alpha-IIb/beta-3	5	Integrin alpha-IIb/beta-3 inhibitor	Approval	https://conductscience.org/library/genes/3674	Drugs and targets

1 to 10 of 221

See all 221 targets

Trials320

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 18 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03817463	A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes		327,624	2024-09-23	Diabetes Mellitus, Type 2	DEXTROSE, EMPAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT01088503	Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome		12,227	2016-01-29	Acute Coronary Syndrome	PRASUGREL	Its record names the disease	ClinicalTrials.gov
NCT02270242	Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention	Phase 4	9,006	2020-08-19	Cardiovascular Disease, Interventional Cardiology	ASPIRIN, TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT00305162	A Clinical Trial to Demonstrate the Efficacy of Cangrelor	Phase 3	8,882	2014-04-23	Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)	CANGRELOR, CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov
NCT02924727	Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI	Phase 3	5,669	2023-06-22	Acute Myocardial Infarction	SACUBITRIL, VALSARTAN	Its record names the disease	ClinicalTrials.gov
NCT00385138	Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.	Phase 3	5,364	2014-04-21	Atherosclerosis, Acute Coronary Syndrome (ACS)	CANGRELOR, CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov
NCT01742117	Tailored Antiplatelet Therapy Following PCI	Phase 4	5,276	2021-11-09	Coronary Artery Disease, Acute Coronary Syndrome, Stenosis	CLOPIDOGREL, TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT00997503	TAXUS Libertē Post Approval Study		4,199	2015-04-13	Coronary Artery Disease	ASPIRIN, PRASUGREL	Its record names the disease	ClinicalTrials.gov
NCT03415152	A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy		3,000	2020-10-12	History of Myocardial Infarction, Hypertriglyceridemia	OMEGA-3-ACID ETHYL ESTERS	Its record names the disease	ClinicalTrials.gov
NCT00046228	A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)	Phase 3	2,461	2009-05-15	Myocardial Infarction	ABCIXIMAB, RETEPLASE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 320

See all 320 trials

Comparisons in its trials128

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause	1,371 of 163,812	2,524 of 163,812	327,624	NCT03817463	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding	19 of 4,374	14 of 4,365	8,739	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of GUSTO Severe / Life-threatening Bleeding	10 of 4,374	11 of 4,365	8,739	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of ACUITY Major Bleeding	151 of 4,374	120 of 4,365	8,739	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of ACUITY Major Bleeding (Without Hematoma >/= 5 cm)	78 of 4,374	65 of 4,365	8,739	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: serious adverse events	125 of 4,374	127 of 4,365	8,739	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, or Unsuccessful Procedure During the Index PCI	127 of 3,897	141 of 3,871	7,768	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)	290 of 3,889	276 of 3,865	7,754	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Individual Incidence of All-cause Mortality	8 of 3,889	5 of 3,865	7,754	NCT00305162	Trial comparisons
Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality and MI	285 of 3,889	261 of 3,865	7,754	NCT00305162	Trial comparisons

1 to 10 of 128

See all 128 comparisons in its trials

Papers from its trials552

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38287198	RESULT	1	PubMed
37777743	RESULT	1	PubMed
37475009	RESULT	1	PubMed
37407956	RESULT	1	PubMed
37236318	RESULT	1	PubMed
36036746	RESULT	1	PubMed
35800360	RESULT	1	PubMed
35268545	RESULT	1	PubMed
34777579	RESULT	1	PubMed
34420373	RESULT	2	PubMed

1 to 10 of 552

See all 552 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005068

GET https://conductscience.org/api/diseases/v1/MONDO_0005068/drugs?page=2

API reference For AI assistants